COMMUNIQUÉS West-GlobeNewswire

Argos Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights

02/04/2018 - 14:30

DURHAM, NC, April 02, 2018 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq: ARGS ), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis [...]

Interpace Diagnostics Announces Coverage of Its Thyroid Assays by Blue Shield of California

02/04/2018 - 14:30

PARSIPPANY, N.J., April 02, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG ) (“Interpace” or “the Company”), a fully integrated commercial and bioinformatics company that provides clinically [...]

Hemispherx Biopharma Announced Financial Results for the Year Ended December 31, 2017

02/04/2018 - 14:30

ORLANDO, Fla., April 02, 2018 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American:HEB), focused on immuno-pharmaceutical research and the commercial development of its immunology products Ampligen® and Alferon [...]

ViaDerma, Inc. Provides an Update of Current and Future Product Sales

02/04/2018 - 14:20

LOS ANGELES, April 02, 2018 (GLOBE NEWSWIRE) -- ViaDerma, Inc., (“Company”) (OTC Pink:VDRM), is pleased to provide a update on current sales of the Company’s flagship product, Vitastem. ViaDerma launches Wound Care [...]

Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer

02/04/2018 - 14:15

Company strengthens management team with biopharmaceutical veteran bringing extensive commercial experience in life-threatening rare diseases Tim Miller, Ph.D. continues as president and assumes chief scientific officer [...]

Albireo to Present at H.C. Wainwright Global Life Sciences Conference

02/04/2018 - 14:00

BOSTON, April 02, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO ), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President [...]

Chimerix to Present at the H.C. Wainwright Annual Global Life Sciences Conference

02/04/2018 - 14:00

DURHAM, N.C., April 02, 2018 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX ), a biopharmaceutical company developing novel antivirals for the growing population of immunocompromised patients, today announced that Garrett [...]

XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced Cancer

02/04/2018 - 14:00

AUSTIN, Texas, April 02, 2018 (GLOBE NEWSWIRE) -- XBiotech USA, Inc. (NASDAQ: XBIT ) announced today that it has obtained an exclusive, worldwide license from CT Atlantic AG (CTA), a Swiss biotechnology company. Under [...]

Women In Bio Closes Boardroom Ready 2018 Applications and Celebrates Board Appointments of Program Alumni

02/04/2018 - 14:00

NEW YORK, April 02, 2018 (GLOBE NEWSWIRE) -- Women In Bio (WIB), an organization of professionals committed to promoting careers, leadership, and entrepreneurship of women in the life sciences, has closed the [...]

Idera Pharmaceuticals Files Definitive Proxy Statement in Connection with Pending Merger with BioCryst Pharmaceuticals

02/04/2018 - 14:00

EXTON, Pa., April 02, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA ) (“Idera”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel [...]

Rhythm Pharmaceuticals Announces Licensing Agreement with Takeda for the Development and Commercialization of Preclinical Treatment for Prader-Willi Syndrome

02/04/2018 - 14:00

-- Oral Ghrelin O-Acyltransferase (GOAT) Inhibitor Complements and Expands Efforts in Prader-Willi Syndrome -- -- In Preclinical Models, Prevented Body Weight Gain and Reduced Fat Mass -- -- Rhythm Expects to File [...]

Aeglea BioTherapeutics Doses First Small Cell Lung Cancer Patients with Pegzilarginase in Both Monotherapy and KEYTRUDA® (Pembrolizumab) Combination Trials

02/04/2018 - 14:00

AUSTIN, Texas, April 02, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE ), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with [...]

Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding Interest under Debentures

02/04/2018 - 14:00

LAVAL, Québec, April 02, 2018 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Corporation”) (NASDAQ: ACST ) (TSX-V: ACST ) announces that in accordance with the terms of its outstanding convertible debentures [...]

Emerald Health Therapeutics Reports 2017 Financial Results and Provides Corporate Update

02/04/2018 - 14:00

VICTORIA, British Columbia, April 02, 2018 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) (“Emerald” or “the Company”) has filed its audited financial statements and management discussion [...]

Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results

02/04/2018 - 14:00

REDWOOD CITY, Calif., April 02, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO ), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases [...]

Inovio Pharmaceuticals to Present at the H.C. Wainwright Annual Global Life Sciences Conference

02/04/2018 - 14:00

PLYMOUTH MEETING, Pa., April 02, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO ) today announced that Dr. J. Joseph Kim, Inovio’s President & CEO, will provide a corporate overview at the H.C. [...]

Abiomed Receives FDA Approval for Impella CP® with SmartAssist™ and Optical Sensor

02/04/2018 - 14:00

DANVERS, Mass., April 02, 2018 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ: ABMD ), a leading provider of breakthrough heart support and recovery technologies, announced today that it has received U.S. Food and Drug [...]

Synergy CHC Corp. Announces Fiscal 2017 Year End Results

02/04/2018 - 13:45

Westbrook, Maine, April 02, 2018 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (OTCQB: SNYR ) (“Synergy” or the “Company”), a consumer health care & beauty company, today reported results for the fiscal year ended December [...]

Strongbridge Biopharma plc Announces Dosing of First Four Patients in LOGICS, a Second Global Phase 3 Study of RECORLEV™ (levoketoconazole) in Endogenous Cushing’s Syndrome

02/04/2018 - 13:30

DUBLIN, Ireland and TREVOSE, Pa., April 02, 2018 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP ), a global commercial-stage biopharmaceutical company focused on the development and commercialization of [...]